AU2016215505B8 - Anti-CD40L antibodies and methods for treating CD40L-related diseases or disorders - Google Patents

Anti-CD40L antibodies and methods for treating CD40L-related diseases or disorders Download PDF

Info

Publication number
AU2016215505B8
AU2016215505B8 AU2016215505A AU2016215505A AU2016215505B8 AU 2016215505 B8 AU2016215505 B8 AU 2016215505B8 AU 2016215505 A AU2016215505 A AU 2016215505A AU 2016215505 A AU2016215505 A AU 2016215505A AU 2016215505 B8 AU2016215505 B8 AU 2016215505B8
Authority
AU
Australia
Prior art keywords
ser
val
leu
thr
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016215505A
Other languages
English (en)
Other versions
AU2016215505B2 (en
AU2016215505A2 (en
AU2016215505A1 (en
Inventor
Alan Gill
Cynthia A. Gill
Bingbing Jiang
John M. Lincecum
Steven N. Perrin
Fernando G. Vieira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALS Therapy Development Institute
Original Assignee
Als Therapy Development Inst
ALS Therapy Development Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Als Therapy Development Inst, ALS Therapy Development Institute filed Critical Als Therapy Development Inst
Publication of AU2016215505A1 publication Critical patent/AU2016215505A1/en
Publication of AU2016215505A2 publication Critical patent/AU2016215505A2/en
Publication of AU2016215505B2 publication Critical patent/AU2016215505B2/en
Application granted granted Critical
Publication of AU2016215505B8 publication Critical patent/AU2016215505B8/en
Priority to AU2022200323A priority Critical patent/AU2022200323B2/en
Priority to AU2024204572A priority patent/AU2024204572A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
AU2016215505A 2015-02-03 2016-02-02 Anti-CD40L antibodies and methods for treating CD40L-related diseases or disorders Active AU2016215505B8 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2022200323A AU2022200323B2 (en) 2015-02-03 2022-01-19 Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders
AU2024204572A AU2024204572A1 (en) 2015-02-03 2024-07-02 Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562111261P 2015-02-03 2015-02-03
US62/111,261 2015-02-03
PCT/US2016/016165 WO2016126702A1 (en) 2015-02-03 2016-02-02 Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022200323A Division AU2022200323B2 (en) 2015-02-03 2022-01-19 Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders

Publications (4)

Publication Number Publication Date
AU2016215505A1 AU2016215505A1 (en) 2017-07-27
AU2016215505A2 AU2016215505A2 (en) 2019-01-24
AU2016215505B2 AU2016215505B2 (en) 2021-10-28
AU2016215505B8 true AU2016215505B8 (en) 2021-11-11

Family

ID=56564599

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2016215505A Active AU2016215505B8 (en) 2015-02-03 2016-02-02 Anti-CD40L antibodies and methods for treating CD40L-related diseases or disorders
AU2022200323A Active AU2022200323B2 (en) 2015-02-03 2022-01-19 Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders
AU2024204572A Pending AU2024204572A1 (en) 2015-02-03 2024-07-02 Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2022200323A Active AU2022200323B2 (en) 2015-02-03 2022-01-19 Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders
AU2024204572A Pending AU2024204572A1 (en) 2015-02-03 2024-07-02 Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders

Country Status (15)

Country Link
US (6) US10106618B2 (enExample)
EP (2) EP4071175A1 (enExample)
JP (4) JP6797810B2 (enExample)
KR (2) KR20250007045A (enExample)
CN (2) CN114195895B (enExample)
AU (3) AU2016215505B8 (enExample)
CA (1) CA2974135A1 (enExample)
DK (1) DK3253412T3 (enExample)
GB (1) GB2552429A (enExample)
IL (3) IL322241A (enExample)
MA (1) MA41459A (enExample)
MX (2) MX392480B (enExample)
RU (1) RU2727646C2 (enExample)
SG (2) SG11201706258WA (enExample)
WO (1) WO2016126702A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012125569A2 (en) 2011-03-11 2012-09-20 Beth Israel Deaconess Medical Center, Inc. Anti-cd40 antibodies and uses thereof
MA41459A (fr) * 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
SI3307322T1 (sl) 2015-09-04 2021-08-31 Primatope Therapeutics Inc. Humanizirana protitelesa proti CD40 in njihove uporabe
AU2018271915B2 (en) * 2017-05-24 2025-03-27 Als Therapy Development Institute Therapeutic anti-CD40 ligand antibodies
LT3993876T (lt) * 2019-07-01 2024-11-11 Tonix Pharma Limited Antikūnai prieš cd154 ir jų panaudojimas
EP3998282A4 (en) * 2019-07-08 2023-08-09 Progen Co., Ltd. NEW FUSION PROTEIN AND ITS USE
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
CN116963750A (zh) * 2021-01-06 2023-10-27 通尼克斯制药有限公司 用经修饰的抗-cd154抗体诱导免疫耐受的方法
WO2022169825A1 (en) 2021-02-03 2022-08-11 Mozart Therapeutics, Inc. Binding agents and methods of using the same
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
CN114149508B (zh) * 2021-11-25 2023-04-28 苏州普乐康医药科技有限公司 一种结合cd40l的融合蛋白及其应用
KR20230108156A (ko) * 2022-01-10 2023-07-18 주식회사 금호에이치티 Cd40l에 특이적으로 결합하는 항체 및 그의 용도
WO2024211211A1 (en) 2023-04-03 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of improving transplant survival using il-2 receptor gamma chain antibodies
WO2025117849A1 (en) 2023-11-28 2025-06-05 Eledon Pharmaceuticals, Inc. Methods and compositions for prevention of transplant rejection
WO2025235670A1 (en) 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Use of anti-cd40 ligand antibodies for immunosuppression in islet cell transplantation
WO2025235683A1 (en) 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Methods and compositions for prevention of transplant rejection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013056068A1 (en) * 2011-10-13 2013-04-18 Bristol-Myers Squibb Company Antibody polypeptides that antagonize cd40l

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5961974A (en) 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
IL104684A0 (en) 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
ATE188487T1 (de) 1993-09-02 2000-01-15 Dartmouth College Anti-gp39 antikoerper und deren verwendungen
US5833987A (en) 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
CA2277222A1 (en) 1997-01-10 1998-07-16 Biogen, Inc. Treatment of lupus nephritis with anti-cd40l compounds
EE9900528A (et) 1997-05-17 2000-06-15 Biogen, Incorporated CD40:CD154 seostumise katkestaja kasutamine adaptiivsete immuunvastuste, eriti transplantaadi hülgamise takistamiseks
CN1173735C (zh) 1998-04-03 2004-11-03 达特茅斯学院理事 抗-gp39抗体在狼疮及相关肾病的治疗和/或逆转中的应用
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
KR20020072277A (ko) 1999-11-08 2002-09-14 아이덱 파마슈티칼즈 코포레이션 항-ｃｄ20 항체 및/또는 화학요법 및 방사선요법과결합하여 항-ｃｄ40ｌ 항체를 이용한 ｂ세포 악성종양의치료방법
EP1975182A1 (en) 2000-02-01 2008-10-01 PanGenetics B.V. CD40-binding APC-activating molecules
GB0006398D0 (en) 2000-03-16 2000-05-03 Novartis Ag Organic compounds
WO2001083755A2 (en) 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
US6797263B2 (en) * 2000-05-12 2004-09-28 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
CA2415100A1 (en) 2000-07-12 2002-01-17 Idec Pharmaceutical Corporation Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
AU8867501A (en) 2000-09-01 2002-03-13 Biogen Inc Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
AU2001287041B2 (en) 2000-09-01 2006-06-08 Biogen Idec Ma Inc. Pyridine derivatives useful as CD40:CD154 binding interruptor compounds and use thereof to treat immunological complications
WO2003074679A2 (en) * 2002-03-01 2003-09-12 Xencor Antibody optimization
WO2004037204A2 (en) 2002-10-25 2004-05-06 University Of South Florida Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease
NZ544486A (en) 2003-06-13 2009-04-30 Biogen Idec Inc Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
WO2005003174A1 (en) 2003-07-08 2005-01-13 Genesto A/S BINDING MEMBER TOWARDS PNEUMOCOCCUS SURFACE ADHESIN A PROTEIN (PsaA)
CA2533593A1 (en) 2003-07-26 2005-02-10 Biogen Idec Ma Inc. Altered antibodies having improved antigen-binding affinity
EP2502935B1 (en) * 2003-08-22 2017-03-29 Biogen MA Inc. Improved antibodies having altered effector function and methods for making the same
US20170166655A1 (en) 2004-03-26 2017-06-15 Xencor, Inc. Novel immunoglobulin variants
EA014226B1 (ru) 2004-07-26 2010-10-29 Байоджен Айдек Ма Инк. Антитела к cd154, их фрагменты и способы применения антител и фрагментов
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
EA013122B1 (ru) * 2005-04-06 2010-02-26 Бристол-Маерс Сквибб Компани Способы лечения иммунных нарушений, связанных с пересадкой трансплантата, растворимым мутантным ctla4
WO2006138316A2 (en) 2005-06-14 2006-12-28 Biogen Idec Ma Inc. Methods for delivering molecules to the central nervous system
KR100772247B1 (ko) 2005-11-04 2007-11-01 엘지전자 주식회사 평면 디스플레이 기기 및 평면 디스플레이 기기의 냉각장치
DK1955078T3 (da) 2005-11-17 2013-09-23 Biogen Idec Inc Blodpladeaggregeringsassays
KR101378194B1 (ko) 2005-12-20 2014-03-27 브리스톨-마이어스 스큅 컴퍼니 안정한 단백질 제제
US7647438B1 (en) * 2006-05-09 2010-01-12 Integrated Device Technology, Inc. Binary base address sorting method and device with shift vector
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
MY166021A (en) * 2007-03-22 2018-05-21 Biogen Ma Inc Binding proteins,including antibodies,antibody derivatives and antibody fragments,that specifically bind cd154 and uses thereof
KR20100021601A (ko) * 2007-05-14 2010-02-25 바이오겐 아이덱 엠에이 인코포레이티드 단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법
UY31987A (es) 2008-07-17 2010-02-26 Novartis Ag Anticuerpos monoclonales o proteinas funcionales antagonistas de baffr , con actividad consumidora de las celulas -b in vivo, composiciones, preparaciones y aplicaciones.
GB0815788D0 (en) 2008-08-29 2008-10-08 Isis Innovation Therapeutic antibodies
EP2367849B1 (en) 2008-12-05 2017-11-01 ALS Therapy Development Institute Method for the treatment of neurodegenerative diseases
US9044459B2 (en) 2008-12-05 2015-06-02 Als Therapy Development Institute Method for the treatment of neurodegenerative diseases
CA2750533A1 (en) * 2009-01-23 2010-07-29 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
WO2012009705A1 (en) * 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
CN103154037A (zh) 2010-10-05 2013-06-12 诺瓦提斯公司 抗IL12Rβ1抗体及它们在治疗自身免疫病和炎性疾病中的用途
WO2012103218A1 (en) 2011-01-25 2012-08-02 University Of South Florida A transgenic model of alzheimer's disease
SI2691417T2 (sl) 2011-03-29 2025-05-30 Roche Glycart Ag FC variante protitelesa
WO2012138768A2 (en) 2011-04-04 2012-10-11 Trustees Of Dartmouth College Anti-cd154 antibodies having impaired fcr binding and/or complement binding properties and the use thereof in immune therapies
US9028826B2 (en) 2011-04-04 2015-05-12 The Trustees Of Dartmouth College Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
TWI598363B (zh) * 2011-04-21 2017-09-11 必治妥美雅史谷比公司 拮抗ｃｄ４０之抗體多肽
EP2748197A2 (en) 2011-08-26 2014-07-02 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
CN103998995B (zh) 2011-12-08 2016-12-28 普雷斯弗雷克斯股份公司 低体积精密波纹管
JP6228971B2 (ja) 2012-05-11 2017-11-08 メディミューン，エルエルシー Ｃｔｌａ−４バリアント
WO2014132101A2 (en) 2012-10-18 2014-09-04 Yongxin Zhang Bioreactor system and methods for alternative cell culture between static and dynamic
CN113621057A (zh) * 2013-04-02 2021-11-09 中外制药株式会社 Fc区变体
EP3041863A4 (en) * 2013-09-05 2017-08-16 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
BR112016018813A2 (pt) * 2014-03-19 2017-10-10 Bristol Myers Squibb Co métodos para tratar rejeição de transplante usando um anticorpo de domínio direcionado contra cd40l
AU2015249656A1 (en) 2014-04-25 2016-11-03 Bristol-Myers Squibb Company Use of CTLA4 compound for achieving drug-free remission in subjects with early RA
US20170233485A1 (en) 2014-08-18 2017-08-17 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
MA41459A (fr) * 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
AU2018271915B2 (en) 2017-05-24 2025-03-27 Als Therapy Development Institute Therapeutic anti-CD40 ligand antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013056068A1 (en) * 2011-10-13 2013-04-18 Bristol-Myers Squibb Company Antibody polypeptides that antagonize cd40l

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAVIS PATRICIA M ET AL, "Abatacept binds to the fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity", JOURNAL OF RHEUMATOLOGY (2007-11-01), vol. 34, no. 11, pages 2204 - 2210 *
J. H. XIE ET AL, "Engineering of a Novel Anti-CD40L Domain Antibody for Treatment of Autoimmune Diseases", THE JOURNAL OF IMMUNOLOGY, (2014-03-26), vol. 192, no. 9, doi:10.4049/jimmunol.1303239, ISSN 0022-1767, pages 4083 - 4092 *

Also Published As

Publication number Publication date
RU2727646C2 (ru) 2020-07-22
AU2016215505B2 (en) 2021-10-28
KR102747565B1 (ko) 2024-12-27
AU2022200323B2 (en) 2024-07-25
RU2017126997A (ru) 2019-03-04
US12275793B2 (en) 2025-04-15
IL253571A0 (en) 2017-09-28
KR20250007045A (ko) 2025-01-13
US20250263493A1 (en) 2025-08-21
US11692040B2 (en) 2023-07-04
US11014990B2 (en) 2021-05-25
US10683356B2 (en) 2020-06-16
JP2025081304A (ja) 2025-05-27
US20200277391A1 (en) 2020-09-03
JP2018510132A (ja) 2018-04-12
CN108064168B (zh) 2021-10-26
US10106618B2 (en) 2018-10-23
AU2016215505A2 (en) 2019-01-24
IL322241A (en) 2025-09-01
CN114195895A (zh) 2022-03-18
JP6797810B2 (ja) 2020-12-09
RU2017126997A3 (enExample) 2019-09-19
JP2021054826A (ja) 2021-04-08
IL287823A (en) 2022-01-01
CN108064168A (zh) 2018-05-22
SG11201706258WA (en) 2017-08-30
US20170342158A1 (en) 2017-11-30
US20190092868A1 (en) 2019-03-28
AU2024204572A1 (en) 2024-09-19
GB201713871D0 (en) 2017-10-11
CN114195895B (zh) 2024-09-06
AU2016215505A1 (en) 2017-07-27
CA2974135A1 (en) 2016-08-11
SG10201912752QA (en) 2020-02-27
WO2016126702A1 (en) 2016-08-11
KR20170108024A (ko) 2017-09-26
MX2017009694A (es) 2018-03-15
EP3253412B1 (en) 2022-03-23
IL253571B (en) 2022-04-01
MX392480B (es) 2025-03-24
NZ733621A (en) 2024-07-05
MA41459A (fr) 2017-12-12
MX2022005655A (es) 2022-06-29
GB2552429A (en) 2018-01-24
EP4071175A1 (en) 2022-10-12
JP2023036717A (ja) 2023-03-14
EP3253412A1 (en) 2017-12-13
EP3253412A4 (en) 2018-08-01
AU2022200323A1 (en) 2022-02-17
US20210269538A1 (en) 2021-09-02
DK3253412T3 (da) 2022-05-23
US20240043549A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
AU2022200323B2 (en) Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders
BRPI0924058B1 (pt) Anticorpos monoclonais, seus usos, bem como composição farmacêutica
US20230242626A1 (en) Composition for treatment and prevention of covid-19
KR20230012538A (ko) 만성 질환에 의한 빈혈을 치료하기 위한 항-헤모주벨린 (hjv) 항체
CN114007645A (zh) 修饰的抗pd-l1抗体及用于治疗神经退行性疾病的方法和用途
CN112805301A (zh) 粒细胞-巨噬细胞集落刺激因子的抗体及其用途
CN119768431A (zh) Igf1r抗体
HK40083008A (en) Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders
HK1245633A1 (en) Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders
HK1245633B (en) Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders
WO2023183926A1 (en) Anti-cd94 antibodies and methods of use thereof

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 24 DEC 2018

TH Corrigenda

Free format text: IN VOL 35 , NO 43 , PAGE(S) 8452 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME ALS THERAPY DEVELOPMENT INSTITUTE, APPLICATION NO. 2016215505, UNDER INID (56) INSERT WO 2013056068 A1

FGA Letters patent sealed or granted (standard patent)